Menu

Primary Menu

Skip to content
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News
Show Header Sidebar Content
Twitter Email LinkedIn

Shift Pharmaceuticals

Author: Steve Oconnor

FDA grants Orphan Drug status for Shift’s lead compound for SMA

Posted onMay 14, 2020May 17, 2020

Shift’s E1V1.11 drug compound to treat Spinal Muscular Atrophy (SMA) granted Orphan Drug Status by FDA. Overland Park: The Food and Drug Administration (FDA) granted orphan drug designation for Shift Pharmaceutical’s lead drug compound to Read More …

TagsShift News Update

Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A treatment

Posted onApril 18, 2020May 17, 2020

CMT Research Foundation funds Shift to explore novel series of drugs created to control the expression of PMP22 gene Overland Park: In late January, the CMT Research Foundation (CMTRF) announced a partnership with Shift Pharmaceuticals Read More …

TagsShift News Update

Shift Pharmaceuticals receives funding from Congressional Directed Medical Research Program (CDMRP)

Posted onMay 19, 2019May 17, 2020

Overland Park: Shift Pharmaceuticals is pleased to announce the Company has been awarded a grant through the Congressional Directed Medical Research Program (CDMRP) to further the development of their initial drug candidate (E1v1.11) for the Read More …

TagsShift News Update

Shift’s News

  • FDA grants Orphan Drug status for Shift’s lead compound for SMA May 14, 2020

Follow Us

Twitter Email LinkedIn

Footer Menu

Skip to content
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News
Copyright © 2022 Shift Pharmaceuticals. All Rights Reserved.
Scroll Up
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News